AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Heart Disease of the Small Arteries in Women and Men

RecruitingNAAges 18 Years - anyAllCedars-Sinai Medical Center
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Women suffer disproportionately than men from Cardiac Syndrome X ( chest pain in the absence of flow limiting coronary artery stenosis). Coronary microvascular disease is hypothesized to mediate chest pain in this syndrome. This disorder of the small heart vessels (arterioles) compared to the large vessels (arteries) is not diagnosed during routine heart catheterization. This results in delays in diagnosis, missed opportunities for treatment, and likely contributes to the increased death rate from coronary heart disease in women compared to men. Current testing for small vessel disease is performed in the cardiac catheterization laboratory using specialized testing and is not performed routinely. Accordingly, women with this condition are either falsely reassured, or misdiagnosed as another non-cardiac condition. Unnecessary healthcare costs related to re-hospitalization and repeat angi

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Women and men with signs and symptoms of myocardial ischemia and angina or angina equivalent (chest pain, abnormal stress testing, abnormal noninvasive testing) or microvascular angina (MVA) which is defined as angina and ischemic ECG changes without organic obstructive stenosis or epicardial spasm of the coronary arteries 2. No obstructive coronary artery disease performed within the previous 24 months (\<50% luminal obstruction in one or more coronary arteries on angiography). 3. Age \> 18 years old 4. Competent to give informed consent Exclusion Criteria: 1. Obstructive CAD โ‰ฅ 50% luminal diameter stenosis in โ‰ฅ 1 epicardial coronary artery, 2. Acute coronary syndrome (defined by the ACC/AHA criteria, Braunwald 2000), 3. Primary valvular heart disease clearly indicating the need for valve repair or replacement; 4. Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support; 5. Prior or planned percutaneous coronary intervention or CABG or prior acute MI in prior 30 days; 6. Prior non-cardiac illness with an estimated life expectancy \<4 years; 7. Unable to give informed consent; 8. Chest pain with a non-ischemic etiology (e.g.,pericarditis, pneumonia, esophageal spasm); 9. Contraindications to adenosine or Regadenoson (Lexiscan) 10. Women and men with intermediate coronary stenoses (\>20% but \<50% luminal diameter stenosis assessed visually at the time of angiography) will undergo clinically indicated IVUS testing based on the judgment of the operator; those determined to have flow FFR or obstructing stenosis will be excluded from the overall study. 11. Heart failure (NYHA Class III or IV on treatment) 12. LV dysfunction (ejection fraction \<40%) 13. Documented obstructive myocardiopathy
๐Ÿ’Š

What it tests

  • noninvasive tests
๐Ÿ“

Where

1 site
Cedars-Sinai Women's Heart Center
Los Angeles, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy